News & Analysis on Clinical Trial Services & Contract Research And Development
Oral drug development company, Phoqus, has announced that it has completed Phase I of its clinical study on Chronocort, the first circadian endocrine treatment for adrenal insufficiency that current steroid therapies for this condition do not mimic.
Dragon Pharmaceutical has bowed out of a development and manufacturing contract with Austria's Polymun Scientific, selling it instead to Swiss company AS Biotech for $1m.
Sigma-Aldrich has strengthened its position in the RNAi and cell-based assay market by signing a series of agreements in which the life science company has acquired a minority equity stake in Genospectra and is granted access to various Genospectra...
Arpida has announced it has successfully completed a Phase I clinical trial with oral iclaprim in a capsule formulation. This broad-spectrum antibiotic targets infections requiring hospital treatment, including those caused by methicillin-resistant...
Biotechnology company, Amgen, and Biovitrum have expanded its existing license agreement for its treatment of metabolic disorders, focusing on type 2 diabetes, which currently afflicts over 160 million people worldwide.
Waters Corporation has introduced new capabilities for proteomic research by enhancing its bioanalysis software, which will allow researchers to identify and quantify proteins and biomarkers more efficiently.
As China improves its resources and regulatory processes it will soon become a hotbed of clinical drug research activity, and position itself as one of the world's most important countries in this field, according to a new report by market research...